EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.
Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.
With its innovative FIT-Ig technology, EpimAb offers a potentially game-changing approach to a broad variety of bi-specific antibodies. The technology provides access to stable bi-specifics by applying conventional molecular biology techniques. FIT-Ig molecules demonstrate properties similar to therapeutically active antibodies. EpimAb is committed to diversifying its portfolio of FIT-Igs in order to further validate the flexibility and robustness of the format and its platform. The broad applicability of this technology enables EpimAb to pursue two concurrent strategies for commercializing the technology:
- Grant licenses to other pharmaceutical companies to combine two antibodies into a FIT-Ig themselves. Through this initiative EpimAb intends to catalyze the broad use of FIT-Igs for the benefit of scientists, the medical community and eventually patients; and
- Create and develop proprietary FIT-Igs enabling EpimAb to grow and develop a discovery and development organization, generate FIT-Igs of great value to patients and medical experts and also improve its technological approach to bi-specific antibodies for the benefit of the scientific community.